Vascular endothelial growth factors and angiogenesis in eye disease

Vascular endothelial growth factors and angiogenesis in eye disease The vascular endothelial growth factor (VEGF) family of growth factors controls pathological angiogenesis and increased vascular permeability in important eye diseases such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). The purpose of this review is to develop new insights into the cell biology of VEGFs and vascular cells in angiogenesis and vascular leakage in general, and to provide the rationale and possible pitfalls of inhibition of VEGFs as a therapy for ocular disease. From the literature it is clear that overexpression of VEGFs and their receptors VEGFR-1, VEGFR-2 and VEGFR-3 is causing increased microvascular permeability and angiogenesis in eye conditions such as DR and AMD. When we focus on the VEGF receptors, recent findings suggest a role of VEGFR-1 as a functional receptor for placenta growth factor (PlGF) and vascular endothelial growth factor-A (VEGF)-A in pericytes and vascular smooth muscle cells in vivo rather than in endothelial cells, and strongly suggest involvement of pericytes in early phases of angiogenesis. In addition, the evidence pointing to distinct functions of VEGFs in physiology in and outside the vasculature is reviewed. The cellular distribution of VEGFR-1, VEGFR-2 and VEGFR-3 suggests various specific functions of the VEGF family in normal retina, both in the retinal vasculature and in neuronal elements. Furthermore, we focus on recent findings that VEGFs secreted by epithelia, including the retinal pigment epithelium (RPE), are likely to mediate paracrine vascular survival signals for adjacent endothelia. In the choroid, derailment of this paracrine relation and overexpression of VEGF-A by RPE may explain the pathogenesis of subretinal neovascularisation in AMD. On the other hand, this paracrine relation and other physiological functions of VEGFs may be endangered by therapeutic VEGF inhibition, as is currently used in several clinical trials in DR and AMD. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Progress in Retinal and Eye Research Elsevier

Vascular endothelial growth factors and angiogenesis in eye disease

Loading next page...
 
/lp/elsevier/vascular-endothelial-growth-factors-and-angiogenesis-in-eye-disease-8r1YpDwrG5
Publisher
Elsevier
Copyright
Copyright © 2003 Elsevier Science Ltd
ISSN
1350-9462
eISSN
1873-1635
D.O.I.
10.1016/S1350-9462(02)00043-5
Publisher site
See Article on Publisher Site

Abstract

The vascular endothelial growth factor (VEGF) family of growth factors controls pathological angiogenesis and increased vascular permeability in important eye diseases such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). The purpose of this review is to develop new insights into the cell biology of VEGFs and vascular cells in angiogenesis and vascular leakage in general, and to provide the rationale and possible pitfalls of inhibition of VEGFs as a therapy for ocular disease. From the literature it is clear that overexpression of VEGFs and their receptors VEGFR-1, VEGFR-2 and VEGFR-3 is causing increased microvascular permeability and angiogenesis in eye conditions such as DR and AMD. When we focus on the VEGF receptors, recent findings suggest a role of VEGFR-1 as a functional receptor for placenta growth factor (PlGF) and vascular endothelial growth factor-A (VEGF)-A in pericytes and vascular smooth muscle cells in vivo rather than in endothelial cells, and strongly suggest involvement of pericytes in early phases of angiogenesis. In addition, the evidence pointing to distinct functions of VEGFs in physiology in and outside the vasculature is reviewed. The cellular distribution of VEGFR-1, VEGFR-2 and VEGFR-3 suggests various specific functions of the VEGF family in normal retina, both in the retinal vasculature and in neuronal elements. Furthermore, we focus on recent findings that VEGFs secreted by epithelia, including the retinal pigment epithelium (RPE), are likely to mediate paracrine vascular survival signals for adjacent endothelia. In the choroid, derailment of this paracrine relation and overexpression of VEGF-A by RPE may explain the pathogenesis of subretinal neovascularisation in AMD. On the other hand, this paracrine relation and other physiological functions of VEGFs may be endangered by therapeutic VEGF inhibition, as is currently used in several clinical trials in DR and AMD.

Journal

Progress in Retinal and Eye ResearchElsevier

Published: Jan 1, 2003

References

  • Renal renin-angiotensin system in diabetes
    Anderson, S; Jung, F.F; Ingelfinger, J.R
  • Endothelium-derived agents in pericyte function/dysfunction
    Chakravarthy, U; Gardiner, T.A
  • Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells
    Chua, C.C; Hamdy, R.C; Chua, B.H
  • Aldose reductase
    Crabbe, M.J; Goode, D
  • Ischemia-driven angiogenesis
    Dor, Y; Keshet, E
  • VEGF regulates cell behavior during vasculogenesis
    Drake, C.J; LaRue, A; Ferrara, N; Little, C.D
  • Vascular endothelial growth factor induces endothelial fenestrations in vitro
    Esser, S; Wolburg, K; Wolburg, H; Breier, G; Kurzchalia, T; Risau, W
  • Vascular permeability factor/endothelial growth factor (VPF/VEGF)
    Fava, R.A; Olsen, N.J; Spencer-Green, G; Yeo, K.T; Yeo, T.K; Berse, B; Jackman, R.W; Senger, D.R; Dvorak, H.F; Brown, L.F
  • Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes
    Gilbert, R.E; Kelly, D.J; Cox, A.J; Wilkinson-Berka, J.L; Rumble, J.R; Osicka, T; Panagiotopoulos, S; Lee, V; Hendrich, E.C; Jerums, G; Cooper, M.E
  • Hepatocyte growth factor/scatter factor in the eye
    Grierson, I; Heathcote, L; Hiscott, P; Hogg, P; Briggs, M; Hagan, S
  • Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis
    Hellstrom, M; Gerhardt, H; Kalen, M; Li, X; Eriksson, U; Wolburg, H; Betsholtz, C
  • The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells
    Kaipainen, A; Korhonen, J; Pajusola, K; Aprelikova, O; Persico, M.G; Terman, B.I; Alitalo, K
  • A novel function of VEGF receptor-2 (KDR)
    Kroll, J; Waltenberger, J
  • A novel vascular endothelial growth factor encoded by Orf virus, VEGF- E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases
    Meyer, M; Clauss, M; Lepple-Wienhues, A; Waltenberger, J; Augustin, H.G; Ziche, M; Lanz, C; Buttner, M; Rziha, H.J; Dehio, C
  • Role of leukocytes in diabetic microcirculatory disturbances
    Miyamoto, K; Ogura, Y; Kenmochi, S; Honda, Y
  • Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues
    Monacci, W.T; Merrill, M.J; Oldfield, E.H
  • Heterogeneity of microvascular pericytes for smooth muscle type alpha-actin
    Nehls, V; Drenckhahn, D
  • Pericyte involvement in capillary sprouting during angiogenesis in situ
    Nehls, V; Denzer, K; Drenckhahn, D
  • Upregulation of pigment epithelium-derived factor after laser photocoagulation
    Ogata, N; Tombran-Tink, J; Jo, N; Mrazek, D; Matsumura, M
  • Growth factors and diabetic retinopathy
    Paques, M; Massin, P; Gaudric, A
  • Vascular endothelial growth factor and glioma angiogenesis
    Plate, K.H; Breier, G; Weich, H.A; Mennel, H.D; Risau, W
  • Development of the Primate Retinal Vasculature
    Provis, J.M
  • Increased expression of endothelial antigen PAL-E in human diabetic retinopathy correlates with microvascular leakage
    Schlingemann, R.O; Hofman, P; Vrensen, G.F; Blaauwgeers, H.G
  • Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1)
    Shibuya, M
  • Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor
    Sondell, M; Sundler, F; Kanje, M
  • Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes
    Sone, H; Kawakami, Y; Okuda, Y; Sekine, Y; Honmura, S; Matsuo, K; Segawa, T; Suzuki, H; Yamashita, K
  • Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy
    Spranger, J; Hammes, H.P; Preissner, K.T; Schatz, H; Pfeiffer, A.F
  • Expression of vascular endothelial growth factor in digestive neuroendocrine tumours
    Terris, B; Scoazec, J.Y; Rubbia, L; Bregeaud, L; Pepper, M.S; Ruszniewski, P; Belghiti, J; Flejou, J; Degott, C
  • Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate
    Tolentino, M.J; McLeod, D.S; Taomoto, M; Otsuji, T; Adamis, A.P; Lutty, G.A
  • Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells
    Tran, J; Rak, J; Sheehan, C; Saibil, S.D; LaCasse, E; Korneluk, R.G; Kerbel, R.S
  • Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice
    Veikkola, T; Jussila, L; Makinen, T; Karpanen, T; Jeltsch, M; Petrova, T.V; Kubo, H; Thurston, G; McDonald, D.M; Achen, M.G; Stacker, S.A; Alitalo, K
  • Molecular cloning of a novel vascular endothelial growth factor, VEGF-D
    Yamada, Y; Nezu, J; Shimane, M; Hirata, Y
  • Time-course expression of vascular endothelial growth factor as related to the development of the retinochoroidal vasculature in rats
    Yi, X; Mai, L.C; Uyama, M; Yew, D.T

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off